RU2014103787A - Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем - Google Patents

Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем Download PDF

Info

Publication number
RU2014103787A
RU2014103787A RU2014103787/15A RU2014103787A RU2014103787A RU 2014103787 A RU2014103787 A RU 2014103787A RU 2014103787/15 A RU2014103787/15 A RU 2014103787/15A RU 2014103787 A RU2014103787 A RU 2014103787A RU 2014103787 A RU2014103787 A RU 2014103787A
Authority
RU
Russia
Prior art keywords
cough
condition accompanied
coughing
disease
oral composition
Prior art date
Application number
RU2014103787/15A
Other languages
English (en)
Russian (ru)
Inventor
Джон Брю
Робин Марк Баннистер
Original Assignee
ИнФёрст Хэлткэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ИнФёрст Хэлткэр Лимитед filed Critical ИнФёрст Хэлткэр Лимитед
Publication of RU2014103787A publication Critical patent/RU2014103787A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014103787/15A 2011-07-05 2012-04-13 Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем RU2014103787A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1111485.7 2011-07-05
GBGB1111485.7A GB201111485D0 (en) 2011-07-05 2011-07-05 Drug composition and its use in therapy
PCT/GB2012/050816 WO2013004999A1 (en) 2011-07-05 2012-04-13 Drug combinations and uses in treating a coughing condition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2016101054A Division RU2016101054A (ru) 2011-07-05 2012-04-13 Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем

Publications (1)

Publication Number Publication Date
RU2014103787A true RU2014103787A (ru) 2015-08-20

Family

ID=44512137

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2014103787/15A RU2014103787A (ru) 2011-07-05 2012-04-13 Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем
RU2016101054A RU2016101054A (ru) 2011-07-05 2012-04-13 Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016101054A RU2016101054A (ru) 2011-07-05 2012-04-13 Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем

Country Status (12)

Country Link
EP (2) EP3251665A1 (https=)
JP (2) JP2014518252A (https=)
KR (1) KR101676454B1 (https=)
CN (1) CN103648488A (https=)
AU (2) AU2012280019B2 (https=)
BR (1) BR112014000159A2 (https=)
CA (1) CA2840793A1 (https=)
GB (1) GB201111485D0 (https=)
MX (1) MX2014000129A (https=)
RU (2) RU2014103787A (https=)
WO (1) WO2013004999A1 (https=)
ZA (1) ZA201400010B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308211B2 (en) 2009-06-16 2016-04-12 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US10016437B2 (en) 2009-06-16 2018-07-10 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB0910375D0 (en) 2009-06-16 2009-07-29 Biocopea Ltd Drug composition and its use in therapy
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
US9314465B2 (en) 2009-06-16 2016-04-19 Infirst Healthcare Limited Drug combinations and uses in treating a coughing condition
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
CN107249621A (zh) * 2014-09-08 2017-10-13 哥谭生物制药股份有限公司 用于治疗肺结节病的粘液溶解剂
CN104436176A (zh) * 2014-11-17 2015-03-25 华东理工大学 一种基于上呼吸道感染及肺炎用的新型生物抗菌喷雾剂
JP7493449B2 (ja) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN109793823A (zh) * 2017-11-17 2019-05-24 中国科学院大连化学物理研究所 一种外用止咳平喘软膏剂及其制备方法
IL318587A (en) * 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20240122934A1 (en) * 2019-10-16 2024-04-18 University Of South Florida Compositions and methods of treatment for inhibiting capillary tube regression
WO2021138578A1 (en) * 2019-12-31 2021-07-08 The Trustees Of Indiana University Repurposing fda-approved drugs as a novel cancer therapeutic avenue through inhibition of prmt5
IL294601A (en) 2020-01-10 2022-09-01 Trevi Therapeutics Inc Methods of administration of nalbuphine
US11628165B1 (en) * 2020-03-25 2023-04-18 Helen Feng Method of boosting immune system against viral infection
KR20250178700A (ko) * 2024-06-18 2025-12-29 가톨릭대학교 산학협력단 낭성콩팥병 개선 또는 치료용 조성물 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20020009478A1 (en) * 1998-08-24 2002-01-24 Douglas Joseph Dobrozsi Oral liquid mucoadhesive compositions
JP2002363072A (ja) * 2001-04-03 2002-12-18 Taisho Pharmaceut Co Ltd 鎮咳用組成物
JP2003081821A (ja) * 2001-09-12 2003-03-19 Taisho Pharmaceut Co Ltd 医薬組成物
JP4377564B2 (ja) * 2002-05-02 2009-12-02 ロート製薬株式会社 内服用組成物
US6979689B2 (en) * 2002-12-20 2005-12-27 Pediamed Pharmaceuticals, Inc. Compositions and methods for treating upper respiratory congestion
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
JP4195895B2 (ja) * 2006-04-04 2008-12-17 小林製薬株式会社 吐出装置を備えた容器に収容される経口投与用液体医薬製剤
US20080003280A1 (en) * 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
EP2421549B1 (en) 2009-04-20 2013-06-12 Allergan, Inc. Silk fibroin hydrogels and uses thereof
GB0919889D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
GB0919893D0 (en) * 2009-11-13 2009-12-30 Biocopea Ltd Drug composition and its use in therapy
GB0921805D0 (en) * 2009-12-14 2010-01-27 Biocopea Ltd Drug composition and its use in therapy
GB201111485D0 (en) * 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
GB201014391D0 (en) * 2010-08-27 2010-10-13 Biocopea Ltd Drug composition and its use in therapy
GB0921803D0 (en) * 2009-12-14 2010-01-27 Biocopea Ltd Drug composition and its use in therapy
UA47594U (uk) * 2009-09-17 2010-02-10 Игорь Викторович Трутаев Комбінований засіб для лікування та профілактики захворювань дихальних шляхів
JP5815226B2 (ja) * 2009-11-30 2015-11-17 興和株式会社 ロキソプロフェンを含有する医薬組成物

Also Published As

Publication number Publication date
WO2013004999A1 (en) 2013-01-10
BR112014000159A2 (pt) 2020-10-27
MX2014000129A (es) 2014-05-28
KR101676454B1 (ko) 2016-11-15
EP2729136A1 (en) 2014-05-14
AU2016256741A1 (en) 2016-12-01
AU2012280019A1 (en) 2014-01-23
GB201111485D0 (en) 2011-08-17
JP2018048189A (ja) 2018-03-29
CA2840793A1 (en) 2013-01-10
AU2012280019B2 (en) 2016-10-27
RU2016101054A3 (https=) 2018-11-19
KR20140037947A (ko) 2014-03-27
ZA201400010B (en) 2015-04-29
JP2014518252A (ja) 2014-07-28
EP3251665A1 (en) 2017-12-06
CN103648488A (zh) 2014-03-19
RU2016101054A (ru) 2018-11-19

Similar Documents

Publication Publication Date Title
RU2014103787A (ru) Комбинации лекарственных средств и их применение в лечении состояния, сопровождающегося кашлем
JP2014518252A5 (https=)
Zhang et al. Research advances in the clinical application of esketamine
JP2010168404A (ja) 睡眠時無呼吸の薬理学的処置
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
CA2910422C (en) Method of treating disease by auricular anesthesia of cranialnerves
EP2964185B1 (en) Preparations for the treatment of sleep-related respiratory disorders
Yang et al. Review of benefits and adverse effects of the most commonly used local anesthetic adjuvants in peripheral nerve blocks.
Bakhtiar et al. Management of Cough
Castillo et al. Effectiveness of mirtazapine in the treatment of sleep apnea/hypopnea syndrome (SAHS)
Yang et al. Combination of ropivacaine hydrochloride and esketamine for thoracic paravertebral block on pain and postoperative recovery of patients undergoing radical resection surgery for lung cancer
RU2009141168A (ru) Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна
JP2009508965A (ja) 正常な呼吸リズムを回復するための組み合わせｓ−ニトロソチオールをベースとする製薬学的製品
CN109464441B (zh) 3-乙酰氨基香豆素在制备治疗或预防高尿酸血症及肾损伤的药物中的应用
Neerati A textbook of pharmacology-III
Nosalova et al. Pharmacological modulation of cough reflex
Paunikar et al. A Textbook of Pharmacology-III
Liu¹t et al. Pharmacological interventions
Muszyński et al. New directions for TENS applications: use beyond pain management.
Ranjan et al. A randomized double blinded study comparing the postoperative analgesic effects of butorphanol, parecoxib and tramadol in patients undergoing major surgical procedures
Arnawa Intranasal premedication: special consideration in children
WO2022246277A2 (en) Drugs for treating neurodevelopmental disorders
Coppola Procedural Sedation
Misrona et al. Devastating Insomnia Experience Following General Anaesthesia for Mastoidectomy Surgery
Pray Cough: options for self treatment